Vistagen Therapeutics unveils new corporate presentation highlighting Phase 3 fasedienol plans and clinical data

Vistagen Therapeutics began using a new corporate presentation summarizing clinical progress and a proposed Phase 3 LSAS trial for fasedienol.Key Highlights:Original SEC Filing: Vistagen Therapeutics, Inc. [ VTGN ] - 8-K - Sep. 25, 2026This is an AI-powered summary. It may contain inaccuracies. Con…